Search

Your search keyword '"Arima, Nobuyoshi"' showing total 41 results
Start Over Author "Arima, Nobuyoshi" Search Limiters Peer Reviewed
41 results on '"Arima, Nobuyoshi"'

1. Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study

Author

Nakamura, Naokazu, Arima, Nobuyoshi, Takakuwa, Teruhito, Yoshioka, Satoshi, Imada, Kazunori, Fukushima, Kentaro, Hotta, Masaaki, Fuchida, Shin-ichi, Kanda, Junya, Uoshima, Nobuhiko, Shimura, Yuji, Tanaka, Hirokazu, Ohta, Kensuke, Kosugi, Satoru, Yagi, Hideo, Yoshihara, Satoshi, Yamamura, Ryosuke, Adachi, Yoko, Hanamoto, Hitoshi, Shibayama, Hirohiko, Hosen, Naoki, Ito, Tomoki, Shimazaki, Chihiro, Takaori-Kondo, Akifumi, Kuroda, Junya, Matsumura, Itaru, and Hino, Masayuki

Published
2024
Full Text
View/download PDF

4. Effects of combined test dose and therapeutic drug monitoring strategy in exposure-directed busulfan

Author

Iemura, Tomoki, Kondo, Tadakazu, Ueda, Atsushi, Maeda, Takeshi, Kitawaki, Toshio, Arai, Yasuyuki, Kanda, Junya, Ikeda, Takashi, Imada, Kazunori, Ishikawa, Takayuki, Anzai, Naoyuki, Itoh, Mitsuru, Takeoka, Tomoharu, Akasaka, Takashi, Yago, Kazuhiro, Yonezawa, Akihito, Arima, Nobuyoshi, Kitano, Toshiyuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Moriguchi, Toshinori, Yamashita, Kouhei, Ueda, Yasunori, Matsumoto, Kana, and Takaori-Kondo, Akifumi

Published
2023
Full Text
View/download PDF

6. Coexistence of HLA and KIR ligand mismatches as a risk factor for viral infection early after cord blood transplantation

Author

Iemura, Tomoki, Arai, Yasuyuki, Kitawaki, Toshio, Kanda, Junya, Kondo, Tadakazu, Ueda, Yasunori, Mori, Takuto, Imada, Kazunori, Yonezawa, Akihito, Yago, Kazuhiro, Anzai, Naoyuki, Kotani, Shinichi, Nohgawa, Masaharu, Kitano, Toshiyuki, Itoh, Mitsuru, Arima, Nobuyoshi, Moriguchi, Toshinori, Watanabe, Mitsumasa, Tsuji, Masaaki, Yamashita, Kouhei, and Takaori-Kondo, Akifumi

Published
2022
Full Text
View/download PDF

7. Establishment of a predictive model for GVHD-free, relapse-free survival after allogeneic HSCT using ensemble learning

Author

Iwasaki, Makoto, Kanda, Junya, Arai, Yasuyuki, Kondo, Tadakazu, Ishikawa, Takayuki, Ueda, Yasunori, Imada, Kazunori, Akasaka, Takashi, Yonezawa, Akihito, Yago, Kazuhiro, Nohgawa, Masaharu, Anzai, Naoyuki, Moriguchi, Toshinori, Kitano, Toshiyuki, Itoh, Mitsuru, Arima, Nobuyoshi, Takeoka, Tomoharu, Watanabe, Mitsumasa, Hirata, Hirokazu, Asagoe, Kosuke, Miyatsuka, Isao, An, Le My, Miyanishi, Masanori, and Takaori-Kondo, Akifumi

Published
2022
Full Text
View/download PDF

9. COVID-19 antibody titers after tixagevimab–cilgavimab injection in patients with hematologic diseases; a single-center, prospective study.

Author

Nakamura, Naokazu, Tsunemine, Hiroko, Ikunari, Ryo, Sakai, Tomomi, and Arima, Nobuyoshi

Subjects
ANTIBODY titer, BLOOD diseases, MULTIPLE regression analysis, LONGITUDINAL method, PSOAS muscles
Abstract

Knowledge of the SARS-CoV-2 antibody titers induced by tixagevimab–cilgavimab in patients with hematologic diseases remains insufficient. Here, we performed a single-center, prospective study to reveal the changes in antibody titer after administration of tixagevimab–cilgavimab in 78 patients with hematologic diseases. The median peak titer was 155.4 U/mL, and the median AUC was 46556 days·U/mL. First, we compared several characteristics between patients with low titers (peak titer ≤ 155.4 U/mL) and high titers (peak titer > 155.4 U/mL). We extracted 6 factors (patient age, sex, ECOG-PS, serum albumin level, and cross-sectional area and computed tomographic number of the psoas major muscle) as candidates influencing the antibody titers. Multiple regression analysis revealed that antibody titer was closely associated with these 6 factors (contribution rate = 0.76, p = 0.02). Our data support the inability of tixagevimab–cilgavimab to induce sufficient antibody titers against SARS-CoV-2, especially in older, frailer, female patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Impact of Donor Source on Allogeneic Hematopoietic Stem Cell Transplantation for Mature T Cell and Natural Killer Cell Neoplasms in the Kyoto Stem Cell Transplantation Group

Author

Watanabe, Mizuki, Kanda, Junya, Arai, Yasuyuki, Hishizawa, Masakatsu, Nishikori, Momoko, Ishikawa, Takayuki, Imada, Kazunori, Ueda, Yasunori, Akasaka, Takashi, Yonezawa, Akihito, Nohgawa, Masaharu, Kitano, Toshiyuki, Itoh, Mitsuru, Takeoka, Tomoharu, Moriguchi, Toshinori, Yago, Kazuhiro, Arima, Nobuyoshi, Anzai, Naoyuki, Watanabe, Mitsumasa, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Published
2020
Full Text
View/download PDF

11. Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study

Author

Arima, Nobuyoshi, Kanda, Junya, Yabe, Toshio, Morishima, Yasuo, Tanaka, Junji, Kako, Shinichi, Sakaguchi, Hirotoshi, Kato, Motohiro, Ohashi, Kazuteru, Ozawa, Yukiyasu, Fukuda, Takahiro, Ota, Shuichi, Tachibana, Takayoshi, Onizuka, Makoto, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Yoshinobu

Published
2020
Full Text
View/download PDF

12. Impact of Homozygous Conserved Extended HLA Haplotype on Single Cord Blood Transplantation: Lessons for Induced Pluripotent Stem Cell Banking and Transplantation in Allogeneic Settings

Author

Morishima, Yasuo, Morishima, Satoko, Murata, Makoto, Arima, Nobuyoshi, Uchida, Naoyuki, Sugio, Yasuhiro, Takahashi, Satoshi, Matsuhashi, Yoshiko, Onizuka, Makoto, Eto, Tetsuya, Nagafuji, Koji, Onishi, Yasushi, Inoue, Masami, Atsuta, Yoshiko, Fukuda, Takahiro, Ichinohe, Tatsuo, Kato, Shunichi, and Kanda, Junya

Published
2020
Full Text
View/download PDF

13. Epitope Mismatch at HLA-DRB1 Associates with Reduced Relapse Risk in Cord Blood Transplantation for Standard-Risk Hematologic Malignancy

Author

Morita-Fujita, Mari, Shindo, Takero, Iemura, Tomoki, Arai, Yasuyuki, Kanda, Junya, Okada, Kazuya, Ueda, Yasunori, Yoshiyuki, Onda, Anzai, Naoyuki, Mori, Takuto, Ishikawa, Takayuki, Otsuka, Yasuyuki, Yonezawa, Akihito, Yuhi, Naoki, Imada, Kazunori, Oba, Akifumi, Itoh, Mitsuru, Okamoto, Yoshio, Kitano, Toshiyuki, Ikeda, Takashi, Kotani, Shinichi, Akasaka, Takashi, Yago, Kazuhiro, Watanabe, Mitsumasa, Nohgawa, Masaharu, Tsuji, Masaaki, Takeoka, Tomoharu, Yamamoto, Ryusuke, Arima, Nobuyoshi, Yoshinaga, Noriyoshi, Hishizawa, Masakatsu, Yamashita, Kouhei, Kondo, Tadakazu, and Takaori-Kondo, Akifumi

Published
2023
Full Text
View/download PDF

15. Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry.

Author

Maeda, Tomoya, Matsuda, Akira, Kanda, Junya, Kawabata, Hiroshi, Ishikawa, Takayuki, Tohyama, Kaoru, Kitanaka, Akira, Araseki, Kayano, Shimbo, Kei, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Usuki, Kensuke, Shindo‐Ueda, Maki, Arima, Nobuyoshi, Nohgawa, Masaharu, Ohta, Akiko, Chiba, Shigeru, Miyazaki, Yasushi, and Nakao, Shinji

Subjects
APLASTIC anemia, DYSPLASIA, AGE differences, OVERALL survival, ADULTS, PAROXYSMAL hemoglobinuria
Abstract

Summary: Morphological dysplasia in haematopoietic cells, defined by a 10% threshold in each lineage, is one of the diagnostic criteria for myelodysplastic neoplasms. Dysplasia limited to the erythroid lineage has also been reported in some cases of aplastic anaemia (AA); however, its significance remains unclear. We herein examined the impact of erythroid dysplasia on immunosuppressive therapy responses and survival in AA patients. The present study included 100 eligible AA patients without ring sideroblasts. Among them, 32 had dysplasia in the erythroid lineage (AA with minimal dysplasia [mini‐D]). No significant sex or age differences were observed between AA groups with and without erythroid dysplasia. In severe/very severe AA and non‐severe AA patients, a response to anti‐thymocyte globulin + ciclosporin within 12 months was observed in 80.0% and 60.0% of AA with mini‐D and 42.9% and 90.0% of those without dysplasia, with no significant difference (p = 0.29 and p = 0.24 respectively). Overall survival and leukaemia‐free survival did not significantly differ between the groups. Collectively, the present results indicate that the presence of erythroid dysplasia did not significantly affect clinical characteristics or outcomes in AA patients, suggesting that its presence in AA is acceptable. Therefore, erythroid dysplasia should not exclude an AA diagnosis. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

16. Interobserver concordance of assessments of dysplasia and blast counts for the diagnosis of patients with cytopenia: From the Japanese central review study

Author

Matsuda, Akira, Kawabata, Hiroshi, Tohyama, Kaoru, Maeda, Tomoya, Araseki, Kayano, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Shimbo, Kei, Usuki, Kensuke, Chiba, Shigeru, Ishikawa, Takayuki, Arima, Nobuyoshi, Nohgawa, Masaharu, Ohta, Akiko, Miyazaki, Yasushi, Nakao, Sinnji, Ozawa, Keiya, Arai, Shunya, Kurokawa, Mineo, Mitani, Kinuko, and Takaori-Kondo, Akifumi

Published
2018
Full Text
View/download PDF

17. Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia

Author

Arima, Nobuyoshi, Kanda, Junya, Tanaka, Junji, Yabe, Toshio, Morishima, Yasuo, Kim, Sung-Won, Najima, Yuho, Ozawa, Yukiyasu, Eto, Tetsuya, Kanamori, Heiwa, Mori, Takehiko, Kobayashi, Naoki, Kondo, Tadakazu, Nakamae, Hirohisa, Uchida, Naoyuki, Inoue, Masami, Fukuda, Takahiro, Ichinohe, Tatsuo, Atsuta, Yoshiko, and Kanda, Yoshinobu

Published
2018
Full Text
View/download PDF

18. Serum ferritin levels at diagnosis predict prognosis in patients with low blast count myelodysplastic syndromes

Author

Kawabata, Hiroshi, Usuki, Kensuke, Shindo-Ueda, Maki, Kanda, Junya, Tohyama, Kaoru, Matsuda, Akira, Araseki, Kayano, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Shimbo, Kei, Chiba, Shigeru, Ishikawa, Takayuki, Arima, Nobuyoshi, Nohgawa, Masaharu, Miyazaki, Yasushi, Kurokawa, Mineo, Arai, Shunya, Mitani, Kinuko, and Takaori-Kondo, Akifumi

Published
2019
Full Text
View/download PDF

20. Influence of Differently Licensed KIR2DL1-Positive Natural Killer Cells in Transplant Recipients with Acute Leukemia: A Japanese National Registry Study

Author

Arima, Nobuyoshi, Nakamura, Fumiaki, Yabe, Toshio, Tanaka, Junji, Fuji, Shigeo, Ohashi, Kazuteru, Fukuda, Takahiro, Miyamura, Koichi, Iwato, Koji, Eto, Tetsuya, Mori, Takehiko, Kobayashi, Naoki, Hoshino, Takumi, Kato, Chiaki, Kanamori, Heiwa, Nakamae, Hirohisa, Atsuta, Yoshiko, Morishima, Yasuo, and Kanda, Yoshinobu

Published
2016
Full Text
View/download PDF

21. Clinical features of Japanese polycythemia vera and essential thrombocythemia patients harboring CALR, JAK2V617F, JAK2Ex12del, and MPLW515L/K mutations

Author

Okabe, Masahiro, Yamaguchi, Hiroki, Usuki, Kensuke, Kobayashi, Yutaka, Kawata, Eri, Kuroda, Junya, Kimura, Shinya, Tajika, Kenji, Gomi, Seiji, Arima, Nobuyoshi, Mori, Sinichiro, Ito, Shigeki, Koizumi, Masayuki, Ito, Yoshikazu, Wakita, Satoshi, Arai, Kunihito, Kitano, Tomoaki, Kosaka, Fumiko, Dan, Kazuo, and Inokuchi, Koiti

Published
2016
Full Text
View/download PDF

22. Validation of the revised International Prognostic Scoring System in patients with myelodysplastic syndrome in Japan: results from a prospective multicenter registry

Author

Kawabata, Hiroshi, Tohyama, Kaoru, Matsuda, Akira, Araseki, Kayano, Hata, Tomoko, Suzuki, Takahiro, Kayano, Hidekazu, Shimbo, Kei, Zaike, Yuji, Usuki, Kensuke, Chiba, Shigeru, Ishikawa, Takayuki, Arima, Nobuyoshi, Nogawa, Masaharu, Ohta, Akiko, Miyazaki, Yasushi, Mitani, Kinuko, Ozawa, Keiya, Arai, Shunya, Kurokawa, Mineo, Takaori-Kondo, Akifumi, and The Japanese National Research Group on Idiopathic Bone Marrow Failure Syndromes

Published
2017
Full Text
View/download PDF

25. Biomarkers for predicting response to corticosteroid therapy for immune thrombocytopenic purpura.

Author

Nakamura, Naokazu, Tsunemine, Hiroko, Sakai, Tomomi, and Arima, Nobuyoshi

Subjects
IDIOPATHIC thrombocytopenic purpura, MONOCYTE lymphocyte ratio, BIOMARKERS, PLATELET count, BONE marrow
Abstract

Summary: Patients with immune thrombocytopenic purpura (ITP) often receive corticosteroids as a first‐line treatment strategy. The ability to predict the therapeutic response to corticosteroids before initiating treatment would reduce the risk of adverse events, but biomarkers of this parameter have not yet been established. Here, in a single‐centre, retrospective, cohort study of 127 ITP patients who received corticosteroids as first‐line treatment, we compared several characteristics and test results between those patients with a favourable response to corticosteroids (responder cohort, n = 68) and those with a poor response to corticosteroids (non‐responder cohort, n = 59) to identify potential biomarkers that were predictive of corticosteroid response. We extracted six factors as indicative of poor response to corticosteroid therapy for ITP: old age (≥81 years) (odds ratio [OR], 2.44; p = 0.02); low platelet count (<9 × 109/L) (OR, 2.25; p = 0.02); high level of platelet‐associated IgG (≥445 ng/107cells) (OR, 3.95; p < 0.01), high platelet distribution width (≥ 14.0 g/dL) (OR, 2.00; p = 0.03), high lymphocyte‐to‐monocyte ratio (≥ 3.52) (OR, 1.40, p = 0.04), and low megakaryocyte count in bone marrow (< 85.5/μl) (OR, 1.72; p = 0.04). Thus, our present data support the fact that these six factors are useful biomarkers for predicting corticosteroid response in patients with ITP. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

28. Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.

Author

Muranushi, Hiroyuki, Kanda, Junya, Kobayashi, Masayuki, Maeda, Takeshi, Kitano, Toshiyuki, Tsuji, Masaaki, Ueda, Yasunori, Ishikawa, Takayuki, Nohgawa, Masaharu, Watanabe, Mitsumasa, Imada, Kazunori, Moriguchi, Toshinori, Itoh, Mitsuru, Ohno, Hitoshi, Yonezawa, Akihito, Hirata, Hirokazu, Arima, Nobuyoshi, Asagoe, Kohsuke, Anzai, Naoyuki, and Nagata, Kayoko

Subjects
MULTIPLE myeloma, BORTEZOMIB, STEM cell transplantation, PROGRESSION-free survival
Abstract

We conducted a phase II trial to prospectively evaluate the efficacy and safety of bortezomib-cyclophosphamide-dexamethasone (VCD) induction, autologous stem cell transplantation (ASCT), VCD consolidation, and bortezomib maintenance in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients in Japan (UMIN000010542). From 2013 to 2016, 42 patients with a median age of 58 (range 42–65) years with NDMM were enrolled in 15 centers. The primary endpoint was the complete response (CR) /stringent CR (sCR) rate after transplantation, and overall/progression-free survival rates were also evaluated. Following induction therapy, the overall response rate was obtained in 71% of patients, including a CR/sCR of 10% and a very good partial response (VGPR) of 26%. Twenty-six of the 42 patients completed ASCT following the protocol and CR/sCR and VGPR rate 100 days after ASCT was 26% and 17%, respectively. During consolidation therapy, 3 of the 24 patients achieved deeper responses. Eight of the 18 patients completed 2-year bortezomib maintenance without disease progression and grade 3/4 toxicities. Five patients were VGPR or partial response after ASCT but maintained response with 2-year bortezomib maintenance. Two-year overall and progression-free survival rates were 92.5% (95% confidence interval [CI]: 78.5%−97.5%) and 62.6% (95% CI: 45.8%−75.5%), respectively. Grade 3/4 toxicities (≥ 10%) included neutropenia (19%) and anemia (17%) in induction, and thrombocytopenia (29%) in consolidation. VCD induction/consolidation and bortezomib maintenance with ASCT for NDMM resulted in a high CR/sCR rate and provided good overall/progression-free survival in Japan. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

34. Primary gastrointestinal follicular lymphoma involving the duodenal second portion is a distinct entity: A multicenter, retrospective analysis in Japan

Author

Takata, Katsuyoshi, Okada, Hiroyuki, Ohmiya, Naoki, Nakamura, Shotaro, Kitadai, Yasuhiko, Tari, Akira, Akamatsu, Taiji, Kawai, Hiroki, Tanaka, Shu, Araki, Hiroshi, Yoshida, Takashi, Okumura, Hirokazu, Nishisaki, Hogara, Sagawa, Tamotsu, Watanabe, Norihiko, Arima, Nobuyoshi, Takatsu, Noritaka, Nakamura, Masanao, Yanai, Shunichi, Kaya, Hiroyasu, Morito, Toshiaki, Sato, Yasuharu, Moriwaki, Hisataka, Sakamoto, Choitsu, Niwa, Yasumasa, Goto, Hidemi, Chiba, Tsutomu, Matsumoto, Takayuki, Ennishi, Daisuke, Kinoshita, Tomohiro, and Yoshino, Tadashi

Published
2011
Full Text
View/download PDF

36. Combination therapy of voriconazole and terbinafine for disseminated fusariosis: case report and literature review.

Author

Inano, Shojiro, Kimura, Masahiro, Iida, Jun, and Arima, Nobuyoshi

Subjects
TERBINAFINE, ANTIFUNGAL agents, FUSARIOSIS, IMMUNOCOMPROMISED patients, DRUG therapy, ENDOCARDITIS, SYSTEMATIC reviews
Abstract

Fusarium spp. cause a broad spectrum of infection and are relatively resistant to most antifungal agents, leading to unfavorable prognosis, especially in immunocompromised patients. Several reports have shown synergism among amphotericin B, voriconazole (VRC), terbinafine (TRB), and other antifungal agents in vitro, but the most efficacious combination remains to be elucidated. We report the first case of disseminated Fusarium solani infection successfully treated by combination therapy of VRC and TRB accompanied by surgical resection of endocardial lesions. We also review 15 case reports of combination antifungal therapy for fusariosis and 6 case reports of Fusarium endocarditis. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

37. Single intra-arterial injection of mesenchymal stromal cells for treatment of steroid-refractory acute graft-versus-host disease: a pilot study.

Author

Arima, Nobuyoshi, Nakamura, Fumiaki, Fukunaga, Akiko, Hirata, Hirokazu, Machida, Hiroko, Kouno, Shigene, and Ohgushi, Hajime

Subjects
*CELL transplantation, *MESENCHYME, *GRAFT versus host disease, *CELLULAR therapy, *INTRA-arterial injections
Abstract

Background aims. Cell therapy with mesenchymal stromal cells (MSC) has been reported recently as a promising treatment for severe acute graft-versus-host disease (GvHD). Methods. We designed a pilot study to treat severe hepatic or gut GvHD using MSC derived from only the donor and cultured without bovine serum. Because the number of cultured MSC is smaller using this method, we planned to treat patients by intra-arterial regional administration directly to the target organs. Results. Three patients were enrolled, and the MSC could be expanded using donor serum. There were no obvious side-effects immediately after arterial injection. The maximum response was partial in one of three patients and did not continue for more than 2 months. Idiopathic pneumonia syndrome developed in two of the three patients. Conclusions. A single local arterial MSC injection was unable to save these patients’ lives and so might not be more effective than multiple systemic intravenous MSC injection. Further clinical research and additional strategies are required to develop appropriate methods for using MSC to achieve extended remission of GvHD. [ABSTRACT FROM AUTHOR]

Published
2010
Full Text
View/download PDF

38. Role of α chain - IL-2 complex in the formation of the ternary complex of IL-2 and high-affinity IL-2 receptor.

Author

Kamio, Masanori, Uchiyama, Takashi, Arima, Nobuyoshi, Itoh, Katsuhlko, Ishikawa, Takayuki, Horl, Toshiyuki, and Uchino, Haruto

Abstract

Using anti-Tac (antl-α chain) and 2R-B (anti-β chain) antibodies, we studied the roles of IL-2 receptor subunits (α and β chains) in the formation of IL-2 and high-affinity IL-2 receptor complex, which is the Initial event of IL-2 induced T cell growth. Hlgh-afflnity IL-2 binding which was undetectable in the presence of 2R-B antibody at 4°C became fully detectable when examined at 37°C, which explained the lack of inhibition by 2R-B antibody of IL-2-lnduced proliferation of the cells expressing high-affinity IL-2 receptor. We further studied the mechanism of the ‘reappearance’ of high-affinity IL-2 binding in the presence of 2R-B antibody. The addition of IL-2 to the cells preincubated with radiolabeled or fluorescence-labeled 2R-B antibody resulted in a marked decrease In the antibody bound to the cells expressing high-affinity IL-2 receptor at 37°C. This decrease was blocked by the presence of anti-Tac antibody, which inhibited IL-2 binding to α chain, but not by 7G7/B6 antibody, which recognized a non-IL-2 binding site of its chain. Furthermore, the decrease in cell-bound 2R-B antibody was not due to the internalization of β chain-2R-B antibody complex, because the amount of cell-bound Mlk-β antibody recognizing a non-IL-2 binding epltope of β chain remained unchanged, nor to the inhibition by simple competitive binding of IL-2 molecules to β chain as judged from comparative studies of competitive binding Inhibition. Taking these data together, the reappearance of high-affinity IL-2 binding was considered to be caused by the replacement of 2R-B antibody at the IL-2 binding site of β chain by α chain-mediated IL-2, and it was strongly suggested that α chain -IL-2 complex has a key role in the formation of the ternary complex of IL-2 and high-afflnlty IL-2 receptor, α chain may function as a dimension converter of IL-2 to effectively deliver IL-2 molecules to a relatively small number of β chains in the dynamics of the formation of hlgh-afflnity IL-2 binding in T cells. [ABSTRACT FROM PUBLISHER]

Published
1990

Catalog

Books, media, physical & digital resources
See catalog results